The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Randomized study of capecitabine versus S-1 in women with metastatic or recurrent breast cancer: Japan Breast Cancer Research Network (JBCRN) 05 trial.
Daigo Yamamoto
No relevant relationships to disclose
Satoru Iwase
No relevant relationships to disclose
Chizuko Yamamoto
No relevant relationships to disclose
Yu Tsubota
No relevant relationships to disclose
Takuhiro Yamaguchi
No relevant relationships to disclose